This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
BALA CYNWYD, Pa.,
July 17, 2012 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Human Genome Sciences, Inc. ("Human Genome" or the "Company") (Nasdaq- HGSI) relating to the proposed acquisition by GlaxoSmithKline plc. ("GSK").
Under the terms of the transaction, Human Genome shareholders will receive only
$14.25 in cash for each of Human Genome stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Human Genome for not acting in the Company's shareholders' best interests in connection with the sale process to GSK. The transaction may undervalue the Company as Human Genome stock traded at
$29.60 a share on
April 28, 2011 and traded at
$14.59 a share as recently as
April 26, 2012. In addition, an analyst has set a price target on Human Genome stock at
$23.00 per share and sales of Human Genome's new lupus drug BENLYSTA reached
$31.2 million for the first quarter of 2012.
If you own shares of Human Genome stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact
Jason L. Brodsky, Esquire or
Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602,
Bala Cynwyd, PA 19004, by e-mail at
http://brodsky-smith.com/453-hgsi-human-genome-sciences-inc.html, or by calling toll free 877-LEGAL-90.
SOURCE Brodsky & Smith, LLC